Proteolysis-targeting chimera molecules targeting SHP2.

Yu, Dandan; Zheng, Mengzhu; Liu, Yang; Chen, Lixia; Li, Hua

Yu, Dandan; Zheng, Mengzhu; Liu, Yang; Chen, Lixia; Li, Hua.

Afiliação

Yu D; Hubei Key Laboratory of Natural Medicinal Chemistry & Resource Evaluation, School of Pharmacy, Tongji-Rongcheng Center for Biomedicine, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, China.
Zheng M; Hubei Key Laboratory of Natural Medicinal Chemistry & Resource Evaluation, School of Pharmacy, Tongji-Rongcheng Center for Biomedicine, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, China.
Liu Y; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Chen L; Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China.
Li H; Hubei Key Laboratory of Natural Medicinal Chemistry & Resource Evaluation, School of Pharmacy, Tongji-Rongcheng Center for Biomedicine, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430030, China.

Future Med Chem ; 14(8): 587-600, 2022 04.

Article em En | MEDLINE | ID: mdl-35297283

Assuntos

Inibidores Enzimáticos; Neoplasias; Humanos; Inibidores Enzimáticos/farmacologia; Neoplasias/tratamento farmacológico; Complexo de Endopeptidases do Proteassoma/metabolismo; Proteólise

Palavras-chave

PROTAC; SHP2; SHP2 PROTAC; SHP2 inhibitor; dual PROTAC

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores Enzimáticos / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google